Na**gel
Transports Combination ***** to
Fight Cancer, Immune Disorders
[IMG]http://www.medgadget.com/wp-content/uploads/2016/04/na**gel_YaleNews.jpg[/IMG]A cutaway illustration of the
Na**gel developed by professor Tarek Fahmy. The small particle can carry multiple drug agents to a specific target, such as the site of a tumor. (Illustration by Nicolle Rager Fuller, NSF)
Yale researchers created a new
Na**gel particle able to carry multiple *****, including immu**therapies, to disease sites such as cancer throughout the body.
The
Na**gel is **w about to be tested*in a clinical trial against cancer by ferrying a
Combination of interleukin-2 (IL-2) and a tissue growth factor (TGF beta) inhibitor. The two
***** are very different chemically and in their size, so transporting them using the same particle type has been challenging before. The
Na**gel solves this problem and encapsulates both in proper concentrations for well targeted delivery.
The IL-2 helps the
Immune system target the cancer while TGF beta inhibitor slows the cancer cells’ ability to avoid the
Immune response.
Some more details according to a Yale an**uncement:
TVM Life Science Ventures VII is providing funding to Modulate Therapeutics Inc. to develop the drug to clinical proof of concept. Modulate secured the rights to IMM-01 from Yale and the Yale start-up company Immu**va L.L.C., which was co-founded by Fahmy, Johns Hopkins University professor of oncology Ephraim Fuchs, and entrepreneur Bernard Friedman.
Source:
Yale…
The post
Na**gel Transports Combination ***** to Fight Cancer, Immune Disorders appeared first on
Medgadget.
